|
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors Clinical research trials and Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors. Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors clinical trial. Human subjects frequently get the finest healthcare available for their Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors  Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
For Condition: unspecified adult solid tumor, protocol specific,lung metastases,liver metastases
Status: No longer recruiting
Sponsor(s): Massey Cancer Center ,
Synopsis: RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue. PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.
Details: OBJECTIVES: - Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors. - Assess the toxicities of this treatment regimen in these patients. - Determine tumor response and cause of death in these patients treated with this regimen. OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed malignancy - Extracranial recurrent or metastatic disease or primary tumor not predicted to be controlled with standard radiotherapy - Incurable with any standard therapy - No tumors involving critical structures (e.g., mucosal surfaces (bowel or bladder) or heart) - Tumor visible by CT scan PATIENT CHARACTERISTICS: Age: - Not specified Performance status: - Karnofsky 60-100% Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Bilirubin less than 2.0 times upper limit of normal (ULN) - AST and ALT less than 5 times ULN Renal: - Creatinine less than 2.0 mg/dL Pulmonary: - FEV1 greater than 0.75 L Other: - No unsuitable size or geometric proportion that would preclude stereotactic immobilization - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 14 days since prior anticancer biologic therapy and recovered Chemotherapy: - At least 14 days since prior anticancer chemotherapy and recovered Endocrine therapy: - At least 14 days since prior anticancer endocrine therapy and recovered Radiotherapy: - See Disease Characteristics - At least 14 days since prior anticancer radiotherapy and recovered Surgery: - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DannySong, Study Chair, Massey Cancer Center
Massey Cancer Center
Richmond, Virginia, 23298-0058
United States
Additional Information:
Study ID Numbers: CDR0000068151; MCV-MCC-9812-2C,NCI-V00-1612
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006456
Other Liver Metastases Studies:
1. Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
2. Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases from Colorectal Cancer
3. Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases from Colorectal Cancer
4. Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
5. Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases from Colorectal Cancer
Related Studies:
Other liver metastases Clinical Trials
Other Virginia Clinical Trials
Other Richmond Clinical Trials
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
|
|
|
|
|
|
|
|
